AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Business Wire
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer Research? (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois.Details on AbCellera’s poster presentation at AACR are as follows:Title: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancerAbstract Number: 6012Session: Therapeutic Antibodies, Including Engineered Antibodies 2Date and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDTLocation: Section 35, Board 7About AbCellera’s T-Cell Engager PlatformCD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on cancer-killing T cells at the same time. However, the develop
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera and Bruker Reach Global Settlement of Patent LitigationBusiness Wire
- AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026Business Wire
- AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]Yahoo! Finance
- Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 12/19/25 - Form 4
- 12/19/25 - Form 3
- 12/19/25 - Form 4
- ABCL's page on the SEC website